FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205885789> ?p ?o ?g. }

• W4205885789 endingPage "970" @default.
• W4205885789 startingPage "962" @default.
• W4205885789 abstract "Rationale: Multimorbidity is common and leads to substantial concomitant medication burden in patients with interstitial lung disease (ILD), which may affect tolerability of ILD-targeted medications and health outcomes. Objectives: To determine the associations of concomitant medication burden with tolerability of ILD-targeted medications and survival in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF ILD. Methods: Patients with IPF receiving nintedanib or pirfenidone and patients with non-IPF ILD receiving azathioprine or mycophenolate were identified from two Australian and Canadian registries. Baseline concomitant medication burden was evaluated using three measures: medication count, polypharmacy (⩾5 medications), and the medication regimen complexity index (MRCI). Medication intolerance and discontinuation were evaluated at 6 months and 1 year after initiation of ILD-targeted medications, respectively. Cox regression models and likelihood ratio tests were used to determine the prognostic significance of medication burden on transplant-free survival. Results: In 645 treated patients with IPF, 43% experienced adverse reactions leading to intolerance (defined as dose reduction, temporary dose interruption, or permanent drug discontinuation) of antifibrotic medications within 6 months of initiation, with high baseline concomitant medication burden being consistently associated with intolerance (medication count: P = 0.005; polypharmacy: P = 0.006; MRCI: P = 0.004). This association was not observed for immunosuppressive medications in 1,255 treated patients with non-IPF ILD, who also had a lower intolerance (18%). Baseline concomitant medication burden was not independently associated with permanent discontinuation of antifibrotic (29%) and immunosuppressive medications (20%) at 1 year. The MRCI was the only measure of concomitant medication burden associated with transplant-free survival in both cohorts (P < 0.01 for both), which improved prognostication beyond common clinical factors and the ILD-GAP index (P < 0.001 for both). Conclusions: Concomitant medication burden is associated with intolerance of antifibrotic medications in patients with IPF. Medication regimen complexity is superior to simpler evaluation of concomitant medication burden for predicting prognosis in ILD." @default.
• W4205885789 created "2022-01-26" @default.
• W4205885789 creator A5002523848 @default.
• W4205885789 creator A5009862886 @default.
• W4205885789 creator A5011774869 @default.
• W4205885789 creator A5023270797 @default.
• W4205885789 creator A5025045708 @default.
• W4205885789 creator A5033032729 @default.
• W4205885789 creator A5033382458 @default.
• W4205885789 creator A5044533146 @default.
• W4205885789 creator A5054075627 @default.
• W4205885789 creator A5072315274 @default.
• W4205885789 creator A5078877643 @default.
• W4205885789 creator A9999999999 @default.
• W4205885789 date "2022-06-01" @default.
• W4205885789 modified "2023-10-05" @default.
• W4205885789 title "Impact of Concomitant Medication Burden on Tolerability of Disease-targeted Therapy and Survival in Interstitial Lung Disease" @default.
• W4205885789 cites W1963867953 @default.
• W4205885789 cites W2000445173 @default.
• W4205885789 cites W2057292199 @default.
• W4205885789 cites W2063946490 @default.
• W4205885789 cites W2102305559 @default.
• W4205885789 cites W2120256142 @default.
• W4205885789 cites W2131450290 @default.
• W4205885789 cites W2138871107 @default.
• W4205885789 cites W2149661971 @default.
• W4205885789 cites W2153972688 @default.
• W4205885789 cites W2167383172 @default.
• W4205885789 cites W2168666423 @default.
• W4205885789 cites W2171466942 @default.
• W4205885789 cites W2199425450 @default.
• W4205885789 cites W2215837199 @default.
• W4205885789 cites W2219832685 @default.
• W4205885789 cites W2328539250 @default.
• W4205885789 cites W2416914730 @default.
• W4205885789 cites W2498506084 @default.
• W4205885789 cites W2507379588 @default.
• W4205885789 cites W2510319197 @default.
• W4205885789 cites W2572971719 @default.
• W4205885789 cites W2763920048 @default.
• W4205885789 cites W2777875601 @default.
• W4205885789 cites W2905932807 @default.
• W4205885789 cites W2916760811 @default.
• W4205885789 cites W2945521814 @default.
• W4205885789 cites W2974960379 @default.
• W4205885789 cites W2975597462 @default.
• W4205885789 cites W2984665308 @default.
• W4205885789 cites W3021593259 @default.
• W4205885789 cites W3096719984 @default.
• W4205885789 cites W3182912085 @default.
• W4205885789 doi "https://doi.org/10.1513/annalsats.202108-980oc" @default.
• W4205885789 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35007498" @default.
• W4205885789 hasPublicationYear "2022" @default.
• W4205885789 type Work @default.
• W4205885789 citedByCount "3" @default.
• W4205885789 countsByYear W42058857892023 @default.
• W4205885789 crossrefType "journal-article" @default.
• W4205885789 hasAuthorship W4205885789A5002523848 @default.
• W4205885789 hasAuthorship W4205885789A5009862886 @default.
• W4205885789 hasAuthorship W4205885789A5011774869 @default.
• W4205885789 hasAuthorship W4205885789A5023270797 @default.
• W4205885789 hasAuthorship W4205885789A5025045708 @default.
• W4205885789 hasAuthorship W4205885789A5033032729 @default.
• W4205885789 hasAuthorship W4205885789A5033382458 @default.
• W4205885789 hasAuthorship W4205885789A5044533146 @default.
• W4205885789 hasAuthorship W4205885789A5054075627 @default.
• W4205885789 hasAuthorship W4205885789A5072315274 @default.
• W4205885789 hasAuthorship W4205885789A5078877643 @default.
• W4205885789 hasAuthorship W4205885789A9999999999 @default.
• W4205885789 hasConcept C126322002 @default.
• W4205885789 hasConcept C197934379 @default.
• W4205885789 hasConcept C2777543607 @default.
• W4205885789 hasConcept C2777714996 @default.
• W4205885789 hasConcept C2778341716 @default.
• W4205885789 hasConcept C2778375690 @default.
• W4205885789 hasConcept C2778715236 @default.
• W4205885789 hasConcept C2779384505 @default.
• W4205885789 hasConcept C2781413609 @default.
• W4205885789 hasConcept C36434225 @default.
• W4205885789 hasConcept C71924100 @default.
• W4205885789 hasConceptScore W4205885789C126322002 @default.
• W4205885789 hasConceptScore W4205885789C197934379 @default.
• W4205885789 hasConceptScore W4205885789C2777543607 @default.
• W4205885789 hasConceptScore W4205885789C2777714996 @default.
• W4205885789 hasConceptScore W4205885789C2778341716 @default.
• W4205885789 hasConceptScore W4205885789C2778375690 @default.
• W4205885789 hasConceptScore W4205885789C2778715236 @default.
• W4205885789 hasConceptScore W4205885789C2779384505 @default.
• W4205885789 hasConceptScore W4205885789C2781413609 @default.
• W4205885789 hasConceptScore W4205885789C36434225 @default.
• W4205885789 hasConceptScore W4205885789C71924100 @default.
• W4205885789 hasFunder F4320306257 @default.
• W4205885789 hasFunder F4320313298 @default.
• W4205885789 hasFunder F4320320593 @default.
• W4205885789 hasIssue "6" @default.
• W4205885789 hasLocation W42058857891 @default.
• W4205885789 hasLocation W42058857892 @default.
• W4205885789 hasOpenAccess W4205885789 @default.

• next